3rd Qtr Earnings
Nothing surprising.
This came out on 11/6/97
biz.yahoo.com
Could this have something to do with the recent drop in price?.....good buying opportunity IMO.
Period from
Feb. 18,
Three Months Nine months 1988
Ended Ended (inception)
Sept. 30, Sept. 30, through
1997 1996 1997 1996 1997
------- ------- ------- ------- --------
Revenue:
Product sales $ 93 $ 129 $ 225 $ 129 $ 355
Earned under research
& development contracts,
substantially from
related parties -- -- -- -- 2,390
Total revenue 93 129 225 129 2,745
Operating expenses:
Product costs 592 710 1,810 710 2,895
Research & development
costs 755 987 2,897 4,558 28,995
Purchased in-process
research & development
costs -- -- -- -- 2,500
Selling, general &
administrative costs 523 1,040 1,709 2,756 15,969
Total expenses 1,870 2,737 6,416 8,024 50,359
Loss from operations (1,777) (2,608) (6,191) (7,895) (47,614)
Interest income, interest
expense & other income (8) 32 44 (123) 23
Loss before income taxes
& extraordinary item (1,785) (2,576) (6,147) (8,018) (47,591)
Income taxes -- -- (2) (2) (65)
Loss before
extraordinary item (1,785) (2,576) (6,149) (8,020) (47,656)
Extraordinary gain on
debt extinguishment -- -- -- -- 485
Net loss (1,785) (2,576) (6,149) (8,020) (47,171)
Less dividends on
mandatorily redeemable
Series A preferred
stock (30) (30) (90) (90) (946)
Net loss attributable to
common stockholders $(1,815) $(2,606) $(6,239) $(8,110) $(48,117)
Net loss per share
attributable to
common stockholders $ (0.17) $ (0.27) $ (0.60) $ (1.00)
Weighted average shares
used to compute net
loss per share
attributable to common
stockholders 10,521 9,723 10,488 8,113
CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY
(A Development Stage Enterprise)
CONSOLIDATED CONDENSED BALANCE SHEET DATA
9/30/97 12/31/96
(Unaudited)
----------- --------
Cash and cash equivalents $ 2,076 $ 7,924
Working capital 250 6,067
Total assets 4,229 10,347
Long-term portion of capital lease
obligations and notes payable 421 764
Mandatorily redeemable Series A preferred stock 1,946 1,856
Total stockholders' equity (deficit) (622) 5,416
Calypte Biomedical Corporation is a Berkeley-based health care company dedicated to the development and commercialization of
urine-based diagnostic products and services for HIV-1, sexually transmitted diseases and other chronic illnesses. Calypte stock is listed
on the Nasdaq SmallCap market under the symbol ''CALY.'' |
